Biora Therapeutics, Inc. announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a drug-device combination consisting of the orally administered NaviCap?? device that delivers a proprietary liquid formulation of tofacitinib to the colon. BT-600 is being developed for the potential treatment of patients with ulcerative colitis (UC).

The MAD portion of the trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo, in healthy adult participants. Biora previously shared positive interim results from the single-ascending dose (SAD) portion of the clinical trial. Highlights from the interim results can be found in the corporate presentation on the company's website.

BT-600 is a drug/device combination designed to use Biora?s NaviCap? ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the potential treatment of moderate to severe ulcerative colitis. The NaviCap device is orally administered and has been designed for targeted therapeutic delivery directly to the colon in this application.